Document is current
Any future updates will be listed below
-
Authors
Kahabuka, Monica S
Woldeamanuel, Yimtubezinash
Mbelele, Peter M.
Mpolya, Emmanuel A.
Mpagama, Stellah G.
Kessy, Jonas P.
Manyazewal, Tsegahun
-
Funding
Funding for this research was provided by:
CDT-Africa, College of Health Sciences, Addis Ababa, University,
DELTAS Africa Initiative (Afrique One-ASPIRE/DEL-15-008)
Fogarty International Center of the US National Institutes of Health (D43TW011404)
National Institute of Allergy and Infectious Diseases (D43TW009127)
- License Information
-
More Information
Article History
Received: 2 November 2022
Accepted: 21 February 2024
First Online: 11 April 2024
Declarations
:
: The proposal has been reviewed and approved by the Scientific and Ethics Review Committee of the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, University, Ethiopia.(REF No:CDT/2467/22), and the National Health Research Ethics Review Committee of the National Institute for Medical Research, Dar es Salaam, Tanzania (REF No:NIMR/HQ/R.8a/Vol.IX/4013). All methods from the study inception to completion were performed in accordance with the relevant guidelines and regulations. Waiver to seek informed consent from the participant was provided by both aforementioned ethical committees i.e. Scientific and Ethics Review Committee of the Center for Innovative Drug Development and Therapeutic Trials for Africa and National Health Research Ethics Review Committee of the National Institute for Medical Research, Dar es Salaam, Tanzania.
: Not applicable.
: All authors declare no conflict of interest.
